JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) just unveiled an announcement.
JW (Cayman) Therapeutics Co. Ltd. has announced a board meeting scheduled for March 27, 2025, to consider and approve the annual audited consolidated results for the year ending December 31, 2024, and potentially recommend a final dividend. This meeting is crucial for stakeholders as it will determine the company’s financial health and strategic decisions moving forward.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on innovative cell therapies. It operates within the healthcare industry, providing advanced therapeutic solutions aimed at addressing unmet medical needs.
YTD Price Performance: 53.12%
Average Trading Volume: 1,304,879
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$814.6M
Learn more about 2126 stock on TipRanks’ Stock Analysis page.